Eli Lilly has partnered with Swedish biotech Alzecure to develop ACD680, a preclinical small-molecule candidate aimed at modulating gamma-secretase, an enzyme linked to amyloid-beta production in Alzheimer’s disease. Following the announcement, Alzecure’s shares surged by 313%. ACD680 represents an innovative approach, targeting the early stages of amyloid production rather than addressing already formed plaques, as seen in other therapies like Lilly’s Kisunla. While Lilly’s Alzheimer’s pipeline now includes three amyloid-targeting assets, the company is also pursuing diverse strategies, including tau-targeting therapies, reflecting a growing complexity in Alzheimer’s research.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://european-biotechnology.com/latest-news/alzecure-shares-soar-over-300-after-eli-lilly-strikes-alzheimers-deal-worth-over-1bn/
